Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
Zai Lab Q2 2024 GAAP Loss Per ADS $(0.82) Misses $(0.70) Estimate, Sales $100.504M Beat $93.136M Estimate
Trending Industry Today: WUXI XDC Leads Gains In Biotech and Pharmaceutical Stocks
WuXi AppTec mid-year analysis: Biomedical industry recovery is already underway | Jian Zhi Research
Looking at the mid-year reports from CXO leaders such as WuXi AppTec, IQVIA, and Lonza, hand orders are exceeding expectations. Among them, WuXi AppTec's new hand order amount (excluding COVID-19 business) increased by 33.2%, far beyond the market expectations. The recovery trend of overseas biotech companies has already emerged.
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
Zai Lab Analyst Ratings
103115047 : In the Middle East war, the demand for medicines will increase dramatically.